Would you give one breath if you could detect lung cancer and other diseases?
Introducing OneBreath™
A unique technology platform developed by Breath Diagnostics to quantitatively analyze organic compounds in a single breath to detect lung cancer and other diseases.1
Our highly portable system will be readily available to patients through medical providers.1
In contrast to a Low-Dose CT Scan, OneBreath is a quicker and easier way of lung cancer diagnosis. We are currently enrolling patients for our 2nd generation system Pilot Study.
Breath Collection
Patients provide one complete breath via a unique collection system in less than 30 seconds.
Breath Processing and Analysis
In a simple automated process, the OneBreath™ micro-reactor captures the organic compounds contained in the breath. Once captured, the samples is analyzed in our laboratories.
Get Results
Results will be available within 3-4 business days.
Why OneBreath™?
OneBreath™ provides a safe, convenient, and inexpensive way to identify lung cancer in at risk patients, before they know they have a problem.1
Accurate Results
OneBreath™ detects lung cancer with fewer false positives and higher specificity than a low-dose CT scan.
Accessible
The OneBreath™ system increases access to potentially life-saving lung cancer screenings by being portable enough for use in a physician's office or local pharmacy.
Affordable
The OneBreath™ technology platform demonstrates a lower false positive rate versus CT scans, reducing the number of unnecessary follow-up diagnostic procedures.
Easy to Use
The simplicity of the OneBreath™ system provides the potential to enhance screening compliance due to the fact that only a single breath is required.
Research & Publications
A Versatile Probe for Chemoselective Capture and Analysis of Carbonyl Compounds in Exhaled Breath
We describe an aminooxy reagent for the capture of trace aldehyde and ketone volatile organic compounds (VOCs) in exhaled breath that, when coated onto micropillars within a silicon microreactor, chemoselectively and covalently retains carbonyl VOCs from exhaled breath.
Research
June 24, 2015
Quantitative Analysis of Exhaled Carbonyl Compounds Distinguishes Benign from Malignant Pulmonary Disease
We report the analysis of exhaled volatile carbonyl compounds for the identification of specific carbonyl cancer markers to differentiate benign pulmonary disease from early-stage lung cancer and to compare its diagnostic accuracy with positron emission tomography (PET) scans.
Research
June 7, 2014
Testimonials
To the promise of breath based lung cancer diagnostics and what Breath diagnostics could offer patients
"Technology like OneBreath has so much potential for improving and saving lives."
Dr. Kevin Gardner
Executive VP Research and Innovation, University of Louisville
OneBreath™ by Breath Diagnostics
OneBreath™ may save your life.
Contact us to discover the future of lung cancer screening or click below to learn more.1
